Dr. Reddy's moved ahead with an "at risk" launch of Indivior's top drug, but now a court has put the rollout on hold.
CANNES, France—Pharma keys in on opportunities to scout talent, show creative work and win awards at 2018 Cannes Lions Health.
Celltrion says its biosimilars for Herceptin and Rituxan could be approved this year after it made plant improvements to resolve and FDA warning letter.
Outcome Health tapped Publicis veteran Matt McNally to take the helm as it steers past a year of media and legal turmoil.
Pharma entries for Cannes Lions Health honors are at a record low, but a bigger-than-ever group of drugmakers made the short list.
Patients in the U.K. won't have access to X-linked hypophosphatemia med Crysvita under a ruling by NICE.
Competition and legal holdups threaten to stifle the launch of Mylan's generic version of of sublingual Suboxone.
Opdivo goes directly to the lucrative lung cancer market with its first nod in China, where nearly 800,000 new patients are diagnosed each year.
FDA clears Sun Pharma's key Halol plant, Eisai builds a new drug discovery center for Alzheimer's, opposition to the Takeda-Shire deal gains support.
England’s cost watchdogs are blocking reimbursement of Roche's Perjeta for some postsurgery patients with early breast cancer.
.jpeg/original (1).jpeg?2zjBv__u5sI6TA74aV3QhttAOSiz26uJ&itok=bpbC_wdD "Bristol-Myers Squibb")
